Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
50–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Weight between 40 and 120 kilograms (Kg) inclusive
Availability of a person (referred to as the "caregiver") who in the investigator's judgment:
Has frequent and sufficient contact with the participant to be able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits (which require partner input for scale completion), signs the necessary consent form, and has sufficient cognitive capacity to accurately report upon the participant's behavior and cognitive and functional abilities
Fluency in the language of the tests used at the study site
Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)
Evidence of the AD pathological process, by a positive amyloid assessment either on cerebrospinal fluid (CSF) amyloid beta 1-42 levels as measured on the Elecsys beta-amyloid(1-42) test system or amyloid PET scan by qualitative read by the core/central PET laboratory
Demonstrated abnormal memory function at screening (up to 4 weeks before screening begins) or screening (FCSRT cueing index =\<0.67 AND free recall =\<27)
Screening mini mental state examination (MMSE) score of greater than or equal to (\>=) 22 points and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 or 1.0
Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment (MCI)
If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening
Participant must have completed at least 6 years of formal education after the age of 5 years
You may not be if
Any evidence of a condition other than AD that may affect cognition such as other dementias, stroke, brain damage, autoimmune disorders (e.g. multiple sclerosis) or infections with neurological sequelae.
History of major psychiatric illness such as schizophrenia or major depression (if not considered in remission)
At risk of suicide in the opinion of the investigator
Any abnormal MRI findings, such as presence of cerebral vascular pathology, cortical stroke, etc or inability to tolerate MRI procedures or contraindication to MRI
Unstable or clinically significant cardiovascular (e.g., myocardial infarction), kidney or liver disease
Uncontrolled hypertension
Screening hemoglobin A1c (HbA1C) \>8%
Poor peripheral venous access
History of cancer except:
If considered to be cured or If not being actively treated with anti-cancer therapy or radiotherapy
\- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins
Clareo Health | A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
